Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Operating Expenses (2023 - 2024)

Zentalis Pharmaceuticals has reported Other Operating Expenses over the past 2 years, most recently at $3.7 million for Q4 2024.

  • For Q4 2024, Other Operating Expenses changed N/A year-over-year to $3.7 million; the TTM value through Sep 2025 reached $3.7 million, changed N/A, while the annual FY2025 figure was -$4000.0, 100.11% down from the prior year.
  • Other Operating Expenses for Q4 2024 was $3.7 million at Zentalis Pharmaceuticals, down from $45.6 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $45.6 million in Q2 2023 and troughed at $3.7 million in Q4 2024.